Avacta Group Plc (FRA:RTQ1)
Germany · Delayed Price · Currency is EUR | Market Cap | 368.07M +15.3% |
| Revenue (ttm) | 131.23K |
| Net Income | -46.35M |
| EPS | -0.11 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,453 |
| Open | 0.7550 |
| Previous Close | 0.7950 |
| Day's Range | 0.7550 - 0.7550 |
| 52-Week Range | 0.5550 - 1.0400 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 15, 2026 |
About Avacta Group
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. The company’s lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. It also develops AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that dri... [Read more]
Financial Performance
In 2025, Avacta Group's revenue was 113,000, a change of 0.00% compared to the previous year's 113,000. Losses were -38.61 million, -26.93% less than in 2024.
Financial numbers in GBP Financial StatementsNews
Half Year 2026 Avacta Group PLC Earnings Presentation Transcript
Half Year 2026 Avacta Group PLC Earnings Presentation Transcript
Avacta H1 Loss Widens As AVA6103 Advances Toward 2027 Data
(RTTNews) - Avacta Group Plc. (AVCT.L), a clinical-stage life sciences company, reported a wider loss before tax for the first half of 2026, compared to the prior year.
Avacta Group plc: Interim Results for the Six Months to June 30, 2026, and Business Update
LONDON and PHILADELPHIA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a life sciences company developing innovative, targeted oncology drugs, today ...
Avacta Group Quarterly report: H1 2026
Avacta Group has published its H1 2026 quarterly earnings report on September 30, 2026.
Avacta Achieves Clinical Proof Of Mechanism For AVA6103 In Phase 1 FOCUS-01 Trial
(RTTNews) - Avacta Group PLC (AVCT.L, AVCTF) announced that its AVA6103, a next-generation controlled-release pre|CISION peptide-drug conjugate, has achieved clinical proof of mechanism in the ongoing...
Avacta Group PLC: Avacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial
LONDON and PHILADELPHIA, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, announces today that it has ach...
Avacta Appoints Blom To Board As Audit Committee Chair; Advances Pre|CISION Platform
(RTTNews) - Avacta Group Plc (AVCT.L), a clinical-stage biopharmaceutical company developing its pre|CISION tumor-activated oncology delivery platform, announced the appointment of Mats Blom to its Bo...
Avacta Group Slides: Corporate presentation
Avacta Group has posted slides in relation to its latest quarterly earnings report, which was published on September 1, 2026.
Avacta Group Slides: FY 2026
Avacta Group has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 22, 2026.
Avacta Group Earnings Call Transcript: H2 2025
Focused on oncology, the company advanced its pre|CISION platform with strong R&D investment, achieved key clinical milestones, and extended its cash runway into early 2027. Multiple clinical data readouts and partnering opportunities are expected in the next 12 months.
Avacta Group Annual report: H2 2025
Avacta Group has published its H2 2025 annual report on May 19, 2026.
Avacta Group Annual report: H2 2025
Avacta Group has published its H2 2025 annual report on May 19, 2026.
Avacta Group Slides: Corporate presentation
Avacta Group has posted slides in relation to its latest quarterly earnings report, which was published on March 4, 2026.
Avacta Group Earnings release: H2 2025
Avacta Group released its H2 2025 earnings on January 20, 2026, summarizing the period's financial results.
Avacta Group Transcript: Study Update
Phase 1B data for AVA6000 in salivary gland cancer show a 90% disease control rate, strong safety profile, and effective tumor targeting even in low-FAP patients. Ongoing enrollment and survival data will inform a randomized Phase 2/3 trial.
Avacta Group Press release: Study Update
Avacta Group issued a press release on December 17, 2025, disclosing material business information to investors.
Avacta Group Slides: Study Update
Avacta Group has posted slides in relation to its latest quarterly earnings report, which was published on December 17, 2025.
Avacta Group Transcript: Status Update
The dual-payload pre|CISION platform enables targeted, simultaneous delivery of two drugs to tumors, overcoming resistance and reducing toxicity. Clinical progress continues with AVA6103 on track for a 2026 trial, a strengthened IP portfolio, and a cash runway into late 2026 supporting multiple upcoming catalysts.
Avacta Group Earnings Call Transcript: H1 2025
Interim results highlight strong clinical progress in oncology programs, with Faridoxorubicin advancing through key trials and AVA6103 on track for clinical entry in 2026. Cash runway extends into Q1 2026, supported by asset sales and bond renegotiation, while strategic partnerships remain a funding priority.
Avacta Group Quarterly report: H1 2025
Avacta Group has published its H1 2025 quarterly earnings report on September 30, 2025.
Avacta Group Slides: H1 2025
Avacta Group has posted slides in relation to its H1 2025 quarterly earnings report, which was published on September 30, 2025.
Avacta Group Slides: Corporate Presentation
Avacta Group has posted slides in relation to its latest quarterly earnings report, which was published on July 23, 2025.
Avacta Group Earnings release: Trading Update
Avacta Group released its earnings on July 2, 2025, summarizing the period's financial results.
Avacta Group Earnings release: Trading Update
Avacta Group released its earnings on July 2, 2025, summarizing the period's financial results.
Avacta Group Transcript: AGM 2025
The AGM highlighted progress in clinical programs, strengthened management, and ongoing financial challenges, particularly the Heights Convertible Bond. Strategic initiatives focus on expanding the precision platform, upcoming data catalysts, and adaptive clinical trial designs.